Description: Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.
Home Page: peartherapeutics.com
PEAR Technical Analysis
200 State Street
Boston,
MA
02109
United States
Phone:
617 925 7848
Officers
Name | Title |
---|---|
Dr. Corey M. McCann M.D., Ph.D. | Founder, Pres, CEO & Director |
Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA | CFO, COO, Treasurer & Assistant Sec. |
Ms. Julia M. Strandberg M.B.A. | Chief Commercial Officer |
Mr. Ronan P. O'Brien J.D. | Chief Compliance Officer, Gen. Counsel & Sec. |
Ms. Meara Murphy | Sr. Director of Corp. Communications |
Dr. Yuri Maricich M.B.A., M.D. | Chief Medical Officer & Head of Devel. |
Mr. Chris Valosky M.B.A. | VP of Sales |
Ms. Katherine Jeffery M.Sc. | Chief People Officer |
Ms. Erin K. Brenner | Chief Product Devel. Officer |
Ms. Ellen E. Snow CPA, CGMA | VP & Corp. Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 4.7008 |
Price-to-Sales TTM: | 21.695 |
IPO Date: | 2021-03-31 |
Fiscal Year End: | December |
Full Time Employees: | 260 |